|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
CN101537180B
(zh)
|
2002-07-18 |
2016-02-10 |
莫鲁斯有限公司 |
抗体混合物的重组生产
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディとその使用
|
|
EP2006381B1
(en)
|
2006-03-31 |
2016-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for controlling blood pharmacokinetics of antibodies
|
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
CA3139492C
(en)
|
2007-09-26 |
2024-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
EP3056513A1
(en)
|
2008-04-11 |
2016-08-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
EP3674317B1
(en)
|
2009-03-19 |
2024-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
RU2522002C2
(ru)
|
2009-06-26 |
2014-07-10 |
Ридженерон Фармасьютикалз, Инк. |
Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
|
|
EP3736338A1
(en)
*
|
2009-09-01 |
2020-11-11 |
F. Hoffmann-La Roche AG |
Enhanced protein purification through a modified protein a elution
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
WO2011078332A1
(ja)
*
|
2009-12-25 |
2011-06-30 |
中外製薬株式会社 |
ポリペプチド多量体を精製するためのポリペプチドの改変方法
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
NZ631363A
(en)
|
2010-02-08 |
2016-05-27 |
Regeneron Pharma |
Common light chain mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
*
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
EA201201435A1
(ru)
*
|
2010-04-20 |
2013-04-30 |
Генмаб А/С |
ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
|
JP5953303B2
(ja)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
改変された等電点を有する抗体
|
|
SG10201912639SA
(en)
*
|
2010-08-02 |
2020-02-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
SG187682A1
(en)
|
2010-08-02 |
2013-03-28 |
Macrogenics Inc |
Covalent diabodies and uses thereof
|
|
CA2815266C
(en)
|
2010-11-05 |
2023-09-05 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
KR101398363B1
(ko)
|
2010-11-17 |
2014-05-22 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
KR101960109B1
(ko)
|
2010-11-30 |
2019-03-20 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
|
TWI761912B
(zh)
|
2010-11-30 |
2022-04-21 |
日商中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
|
WO2012132067A1
(ja)
*
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
|
SG10201609665PA
(en)
*
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
KR102403848B1
(ko)
*
|
2011-03-30 |
2022-05-30 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법
|
|
CA2836873C
(en)
|
2011-05-21 |
2019-10-22 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
EP4011913A1
(en)
|
2011-06-30 |
2022-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
DK2739740T3
(da)
|
2011-08-05 |
2019-12-09 |
Regeneron Pharma |
Universelle, humaniserede letkæde-mus
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CN108200885B
(zh)
*
|
2011-10-17 |
2021-12-14 |
瑞泽恩制药公司 |
受限制的免疫球蛋白重链基因座
|
|
LT2771364T
(lt)
|
2011-10-27 |
2019-09-10 |
Genmab A/S |
Heterodimerinių baltymų gamyba
|
|
EP2787078B1
(en)
|
2011-10-31 |
2019-05-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
WO2014067011A1
(en)
|
2012-11-02 |
2014-05-08 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
|
HRP20211773T1
(hr)
|
2011-11-04 |
2022-03-04 |
Zymeworks Inc. |
Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
|
|
PL2780368T3
(pl)
|
2011-11-14 |
2018-06-29 |
Regeneron Pharmaceuticals, Inc. |
Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
|
|
HUE048597T2
(hu)
|
2011-11-18 |
2020-07-28 |
Regeneron Pharma |
Módszer polimerbevonatú fehérje-mikrorészecskéket tartalmazó, elnyújtott hatóanyag-kibocsátású gyógyszerészeti készítmény gyártására porlasztva szárítással
|
|
EP2787081A4
(en)
|
2011-11-30 |
2015-10-07 |
Chugai Pharmaceutical Co Ltd |
PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
|
|
PL2794905T3
(pl)
*
|
2011-12-20 |
2020-11-02 |
Medimmune, Llc |
Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
|
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
|
MX2014010527A
(es)
|
2012-03-02 |
2014-10-14 |
Regeneron Pharma |
Anticuerpos humanos para toxinas de clostridium difficile.
|
|
KR20140136462A
(ko)
|
2012-03-06 |
2014-11-28 |
리제너론 파마슈티칼스 인코포레이티드 |
공통 경쇄 마우스
|
|
EP3517548A1
(en)
|
2012-03-13 |
2019-07-31 |
NovImmune S.A. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
NZ629077A
(en)
|
2012-03-16 |
2015-12-24 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
PT2825036T
(pt)
|
2012-03-16 |
2018-07-26 |
Regeneron Pharma |
Anticorpos de cadeia leve manipulados em histidina e roedores geneticamente modificados para gerar os mesmos
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
RS59263B1
(sr)
|
2012-04-20 |
2019-10-31 |
Merus Nv |
Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
|
|
CA2871807C
(en)
|
2012-04-27 |
2022-10-04 |
Bioatla, Llc |
Modified antibody regions and uses thereof
|
|
LT3597037T
(lt)
|
2012-06-12 |
2021-06-10 |
Regeneron Pharmaceuticals, Inc. |
Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
|
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたＦｃ領域を含む抗原結合分子
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
EP3721900A1
(en)
|
2012-08-24 |
2020-10-14 |
Chugai Seiyaku Kabushiki Kaisha |
Fcgammariib-specific fc region variant
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
WO2014049003A1
(en)
|
2012-09-25 |
2014-04-03 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
SG10201705787VA
(en)
|
2012-09-27 |
2017-08-30 |
Merus Nv |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
|
US9714291B2
(en)
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
|
WO2014069647A1
(ja)
|
2012-11-05 |
2014-05-08 |
全薬工業株式会社 |
抗体又は抗体組成物の製造方法
|
|
TWI864338B
(zh)
*
|
2012-11-14 |
2024-12-01 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
|
CN120173125A
(zh)
|
2012-11-28 |
2025-06-20 |
酵活英属哥伦比亚有限公司 |
工程化免疫球蛋白重链-轻链对及其用途
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
WO2014104165A1
(ja)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
KR20220156667A
(ko)
|
2013-01-10 |
2022-11-25 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN110981964B
(zh)
|
2013-01-14 |
2023-09-15 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
TWI682941B
(zh)
*
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
DK2840892T3
(en)
|
2013-02-20 |
2018-07-23 |
Regeneron Pharma |
Non-human animals with modified heavy chain immunoglobulin sequences
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
CN108611369B
(zh)
|
2013-03-13 |
2022-08-26 |
瑞泽恩制药公司 |
表达限制的免疫球蛋白轻链库的小鼠
|
|
CA2903696A1
(en)
|
2013-03-13 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
CA2906566C
(en)
|
2013-03-14 |
2024-09-10 |
Macrogenics Inc |
Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
|
|
ES2735354T3
(es)
*
|
2013-03-14 |
2019-12-18 |
Emd Millipore Corp |
Métodos para aumentar la pureza de proteínas utilizando la cromatografía basada en proteína A
|
|
MX369574B
(es)
|
2013-03-14 |
2019-11-13 |
Regeneron Pharma |
Anticuerpos humanos contra grem1.
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
TWI636062B
(zh)
|
2013-04-02 |
2018-09-21 |
中外製藥股份有限公司 |
Fc region variant
|
|
US11357866B2
(en)
*
|
2013-04-03 |
2022-06-14 |
The Administrators Of The Tulane Educational Fund |
Expression of HIV inhibitors by mesenchymal stem cells
|
|
ES2871383T3
(es)
*
|
2013-04-29 |
2021-10-28 |
Hoffmann La Roche |
Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso
|
|
CN105143262A
(zh)
|
2013-04-29 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
结合人fcrn的修饰的抗体和使用方法
|
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
WO2015033223A2
(en)
*
|
2013-09-03 |
2015-03-12 |
Novimmune S.A. |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
|
CN104418947A
(zh)
*
|
2013-09-11 |
2015-03-18 |
香港大学 |
抗her2和抗-igf-ir的双特异性抗体及其用途
|
|
LT3046412T
(lt)
|
2013-09-18 |
2019-07-25 |
Regeneron Pharmaceuticals, Inc. |
Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai
|
|
DK3050896T3
(da)
*
|
2013-09-27 |
2021-07-19 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
|
|
PE20160724A1
(es)
|
2013-11-04 |
2016-08-04 |
Glenmark Pharmaceuticals Sa |
Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
|
|
EA201691027A1
(ru)
|
2013-11-20 |
2016-12-30 |
Ридженерон Фармасьютикалз, Инк. |
Модуляторы aplnr и их применение
|
|
PL3074424T3
(pl)
|
2013-11-27 |
2025-06-09 |
Zymeworks Bc Inc. |
Bispecyficzne konstrukty wiążące antygen ukierunkowane na her2
|
|
HUE050156T2
(hu)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
JP2017029001A
(ja)
*
|
2013-12-19 |
2017-02-09 |
国立研究開発法人産業技術総合研究所 |
プロテインｇの細胞膜外ドメインの新規な改変型タンパク質
|
|
WO2015107015A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with improved protein a-binding
|
|
JP6786392B2
(ja)
|
2014-01-15 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
HK1231374A1
(zh)
*
|
2014-02-21 |
2017-12-22 |
Regeneron Pharmaceuticals, Inc. |
用於靶抗原的细胞特异性调变的方法、组合物和试剂盒
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
SI3110849T1
(sl)
|
2014-02-28 |
2021-01-29 |
Merus N.V. |
Protitelo, ki veže ERBB-2 in ERBB-3
|
|
TWI701042B
(zh)
*
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
KR102601491B1
(ko)
|
2014-03-21 |
2023-11-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
AU2015237184B2
(en)
|
2014-03-28 |
2020-11-26 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
|
TWI726842B
(zh)
|
2014-04-07 |
2021-05-11 |
日商中外製藥股份有限公司 |
免疫活化抗原結合分子
|
|
KR20170017916A
(ko)
*
|
2014-05-13 |
2017-02-15 |
추가이 세이야쿠 가부시키가이샤 |
면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
US10155818B2
(en)
|
2014-05-28 |
2018-12-18 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
KR102493430B1
(ko)
|
2014-05-28 |
2023-01-31 |
자임워크스 비씨 인코포레이티드 |
변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
|
|
TWI742423B
(zh)
|
2014-05-29 |
2021-10-11 |
美商宏觀基因股份有限公司 |
特異性結合多種癌症抗原的三特異性結合分子和其使用方法
|
|
AR101262A1
(es)
*
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CA2963991A1
(en)
|
2014-09-29 |
2016-04-07 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
KR20170078677A
(ko)
|
2014-11-06 |
2017-07-07 |
에프. 호프만-라 로슈 아게 |
Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
|
|
MX2017005150A
(es)
*
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
|
RS60739B1
(sr)
|
2014-11-17 |
2020-09-30 |
Regeneron Pharma |
Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
|
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
MX384025B
(es)
|
2014-11-26 |
2025-03-14 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
|
|
PE20171103A1
(es)
|
2014-11-26 |
2017-08-07 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
DK3029137T3
(en)
|
2014-12-06 |
2019-04-08 |
Gemoab Monoclonals Gmbh |
GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
|
|
TWI702229B
(zh)
|
2014-12-19 |
2020-08-21 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
EP3237450B1
(en)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
AU2016233309B2
(en)
|
2015-03-17 |
2021-11-18 |
Memorial Sloan Kettering Cancer Center |
Anti-MUC16 antibodies and uses thereof
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
TW202523853A
(zh)
|
2015-03-27 |
2025-06-16 |
美商再生元醫藥公司 |
偵測生物污染物之組成物及方法
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
EP3283519A1
(en)
|
2015-04-15 |
2018-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of increasing strength and functionality with gdf8 inhibitors
|
|
JP7240812B2
(ja)
|
2015-05-12 |
2023-03-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多量体タンパク質の純度の決定
|
|
EP3736290A1
(en)
|
2015-05-29 |
2020-11-11 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
KR20250091329A
(ko)
|
2015-06-15 |
2025-06-20 |
누맙 세러퓨틱스 아게 |
이종 이량체 다중 특이적 항체 포맷
|
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
|
AU2016284871B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific NK engager proteins
|
|
ES2971045T3
(es)
|
2015-07-06 |
2024-06-03 |
Regeneron Pharma |
Moléculas multiespecíficas de unión a antígeno y usos de las mismas
|
|
EP3319996B1
(en)
|
2015-07-09 |
2024-01-03 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
CN108026174B
(zh)
|
2015-07-10 |
2023-02-17 |
美勒斯公司 |
人cd3结合抗体
|
|
US20180326084A1
(en)
|
2015-07-10 |
2018-11-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
BR112017026543A2
(pt)
*
|
2015-08-26 |
2018-08-14 |
Bison Therapeutics Inc |
plataforma de anticorpo multiespecífico e métodos relacionados
|
|
CA2993432A1
(en)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
HRP20250094T1
(hr)
|
2015-10-08 |
2025-03-28 |
Zymeworks Bc Inc. |
Polipeptidni konstrukti koji se vežu na antigen koji sadrže kappa i lambda lake lance i njihova uporaba
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
HRP20210483T1
(hr)
|
2015-10-23 |
2021-07-09 |
Merus N.V. |
Vezujuće molekule koje inhibiraju rast raka
|
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
US20190202926A1
(en)
|
2015-12-01 |
2019-07-04 |
Genmab B.V. |
Anti-death receptor antibodies and methods of use thereof
|
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
CA3009161A1
(en)
|
2015-12-22 |
2017-06-29 |
Regeneron Pharmaceuticals, Inc. |
Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
|
|
MX2018007781A
(es)
*
|
2015-12-28 |
2018-09-05 |
Chugai Pharmaceutical Co Ltd |
Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
|
|
GB201602156D0
(en)
*
|
2016-02-05 |
2016-03-23 |
Jones Philip C And Boku University Of Natural Resources And Life Sciences |
Heterodimers and purification thereof
|
|
TW202342540A
(zh)
|
2016-03-14 |
2023-11-01 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
SG10202010156XA
(en)
|
2016-04-20 |
2020-11-27 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
|
CN109195986B
(zh)
|
2016-04-20 |
2023-01-03 |
瑞泽恩制药公司 |
基于使用表达增强性基因座来制备抗体的组合物和方法
|
|
BR112018067792A2
(pt)
|
2016-04-28 |
2019-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
preparação contendo o anticorpo
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
WO2017194597A1
(en)
|
2016-05-11 |
2017-11-16 |
Ge Healthcare Bioprocess R&D Ab |
Separation matrix
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
CN109311949B
(zh)
|
2016-05-11 |
2022-09-16 |
思拓凡生物工艺研发有限公司 |
储存分离基质的方法
|
|
JP6987424B2
(ja)
|
2016-05-11 |
2022-01-05 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックスを洗浄および／または消毒する方法
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
TW202408578A
(zh)
|
2016-05-13 |
2024-03-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
IL262888B1
(en)
|
2016-05-20 |
2025-10-01 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide RNAs
|
|
US10639368B2
(en)
|
2016-05-27 |
2020-05-05 |
Agenus Inc. |
Anti-TIM-3 antibodies and methods of use thereof
|
|
DK3468586T3
(da)
|
2016-06-14 |
2024-10-21 |
Xencor Inc |
Bispecifikke checkpoint-hæmmer-antistoffer
|
|
MY191668A
(en)
|
2016-06-14 |
2022-07-06 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
CN109790526A
(zh)
|
2016-07-01 |
2019-05-21 |
分解治疗有限责任公司 |
优化的二核酸酶融合体和方法
|
|
KR20190039937A
(ko)
|
2016-07-08 |
2019-04-16 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018058001A1
(en)
|
2016-09-23 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
|
WO2018058003A1
(en)
|
2016-09-23 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-muc16 (mucin 16) antibodies
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
IL265800B2
(en)
|
2016-10-11 |
2023-10-01 |
Agenus Inc |
Anti-LAG-3 antibodies and methods of using them
|
|
UA128669C2
(uk)
|
2016-10-14 |
2024-09-25 |
Ксенкор, Інк. |
ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
|
|
KR20190070977A
(ko)
|
2016-11-01 |
2019-06-21 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
MX2019005438A
(es)
|
2016-11-15 |
2019-08-16 |
Genentech Inc |
Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
|
|
MX2019006340A
(es)
|
2016-12-07 |
2019-11-07 |
Agenus Inc |
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
|
|
BR112019012354A2
(pt)
|
2016-12-21 |
2019-11-26 |
Teneobio Inc |
anticorpos apenas de cadeia pesada anti-bcma
|
|
EP3559032A1
(en)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
TWI781130B
(zh)
|
2017-01-03 |
2022-10-21 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
|
|
EP3581651A4
(en)
|
2017-02-07 |
2021-05-12 |
Daiichi Sankyo Company, Limited |
ANTI-GPRC5D ANTIBODY AND MOLECULE WITH IT
|
|
MA47449A
(fr)
|
2017-02-10 |
2019-12-18 |
Genmab Bv |
Variants polypeptidiques et ses utilisations
|
|
JP7167041B2
(ja)
|
2017-02-10 |
2022-11-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
KR20240049621A
(ko)
|
2017-02-17 |
2024-04-16 |
사노피 |
디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
|
|
US10626169B2
(en)
|
2017-02-17 |
2020-04-21 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
EP4659808A2
(en)
|
2017-02-17 |
2025-12-10 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
EP3589650A1
(en)
|
2017-03-02 |
2020-01-08 |
Novartis AG |
Engineered heterodimeric proteins
|
|
US20200330590A1
(en)
|
2017-03-27 |
2020-10-22 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
BR112019020219A2
(pt)
|
2017-03-31 |
2020-11-24 |
Genmab Holding B.V. |
anticorpo biespecífico, anticorpo anti-cd37, composição farmacêutica, uso do anticorpo biespecífico, do anticorpo anti-cd37 ou da composição farmacêutica, método para induzir a morte celular, ou inibir o crescimento e/ou a proliferação de uma célula tumoral que expressa cd37, método de tratamento, construto de ácido nucleico, vetor de expressão, célula hospedeira, anticorpo anti-idiotípico, e, método in vitro para detectar a presença de um antígeno cd37 humano ou uma célula que expressa cd37 humano.
|
|
MX2019011660A
(es)
|
2017-03-31 |
2019-11-18 |
Merus Nv |
Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
KR102732040B1
(ko)
|
2017-04-11 |
2024-11-21 |
인히브릭스 바이오사이언스, 인크. |
제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
WO2018204363A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
ES2951864T3
(es)
|
2017-05-17 |
2023-10-25 |
Merus Nv |
Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
EP3635014B1
(en)
|
2017-06-05 |
2023-09-27 |
Numab Therapeutics AG |
Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
|
|
MX2019014576A
(es)
*
|
2017-06-05 |
2020-07-29 |
Janssen Biotech Inc |
Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
|
|
KR102760654B1
(ko)
|
2017-06-07 |
2025-02-04 |
리제너론 파마슈티칼스 인코포레이티드 |
효소 내재화를 위한 조성물 및 방법
|
|
MA49259A
(fr)
|
2017-06-07 |
2020-04-15 |
Genmab Bv |
Anticorps thérapeutiques à base d'hexamères d'igg mutées
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
|
WO2019006034A1
(en)
|
2017-06-27 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS
|
|
PT3645551T
(pt)
|
2017-06-27 |
2024-05-13 |
Regeneron Pharma |
Vetores virais recombinantes com tropismo modificado e utilizações dos mesmos para a introdução direcionada de material genético em células humanas
|
|
KR102574549B1
(ko)
|
2017-06-27 |
2023-09-07 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
|
IL299348B2
(en)
|
2017-06-28 |
2025-05-01 |
Regeneron Pharma |
Antigen-binding proteins against human papillomavirus and methods of using them
|
|
CA3068672A1
(en)
|
2017-06-28 |
2019-01-03 |
The Rockefeller University |
Anti-mertk agonistic antibody-drug conjugates and uses thereof
|
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
|
|
CN111566214B
(zh)
*
|
2017-07-06 |
2024-03-08 |
日东纺绩株式会社 |
抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂
|
|
AU2018298039B2
(en)
|
2017-07-06 |
2023-02-02 |
Regeneron Pharmaceuticals, Inc. |
Cell culture process for making a glycoprotein
|
|
TWI865430B
(zh)
|
2017-07-24 |
2024-12-11 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
ES3023158T3
(en)
*
|
2017-08-01 |
2025-05-30 |
Ab Therapeutics Inc |
Bispecific antibodies and uses thereof
|
|
JP7079171B2
(ja)
|
2017-08-03 |
2022-06-01 |
アムジエン・インコーポレーテツド |
インターロイキン－２１ムテイン及び治療方法
|
|
KR20200042485A
(ko)
|
2017-08-09 |
2020-04-23 |
메뤼스 엔.페. |
EGFR 및 cMET에 결합하는 항체
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
KR102777015B1
(ko)
|
2017-08-22 |
2025-03-10 |
사나바이오, 엘엘씨 |
가용성 인터페론 수용체 및 그의 용도
|
|
MX2020002502A
(es)
|
2017-09-08 |
2020-07-20 |
Amgen Inc |
Inhibidores de kras g12c y metodos para utilizarlos.
|
|
EP3681909A1
(en)
*
|
2017-09-14 |
2020-07-22 |
Denali Therapeutics Inc. |
Anti-trem2 antibodies and methods of use thereof
|
|
BR112020004977A2
(pt)
|
2017-09-29 |
2020-10-06 |
Regeneron Pharmaceuticals, Inc. |
moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos
|
|
CA3071712C
(en)
|
2017-09-29 |
2023-02-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus and methods of use
|
|
CA3076630A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
Transthyretin immunoglobulin fusions
|
|
BR112020007154A2
(pt)
|
2017-10-20 |
2020-09-29 |
F. Hoffmann-La Roche Ag |
método para produzir um polipeptídeo e polipeptídeos heterodimérico
|
|
TWI832824B
(zh)
|
2017-10-30 |
2024-02-21 |
瑞士商赫孚孟拉羅股份公司 |
自單特異性抗體於活體內產生多特異性抗體之方法
|
|
MA50516A
(fr)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs procédés d'utilisation
|
|
WO2019088143A1
(ja)
|
2017-11-01 |
2019-05-09 |
中外製薬株式会社 |
生物活性が低下した抗体バリアントおよびアイソフォーム
|
|
MX2020004561A
(es)
*
|
2017-11-02 |
2020-08-13 |
Bayer Ag |
Anticuerpos biespecificos que se unen a alk-1 y bmpr-2.
|
|
CN111741757B
(zh)
*
|
2017-11-03 |
2023-12-19 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2019101695A1
(en)
|
2017-11-21 |
2019-05-31 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
US11419318B2
(en)
|
2017-11-30 |
2022-08-23 |
Regeneran Pharmaceuticals, Inc. |
Genetically modified rat comprising a humanized TRKB locus
|
|
MA51147A
(fr)
|
2017-12-13 |
2021-03-24 |
Regeneron Pharma |
Associations d'anticorps anti-c5 et utilisations associées
|
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
AU2018392334A1
(en)
|
2017-12-22 |
2020-05-28 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
|
AU2018387829B2
(en)
*
|
2017-12-22 |
2024-12-19 |
Argenx Bvba |
Bispecific antigen binding construct
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
US11518808B2
(en)
|
2018-01-12 |
2022-12-06 |
Amgen Inc. |
Anti-PD-1 antibodies and methods of treatment
|
|
EP3743440A1
(en)
|
2018-01-24 |
2020-12-02 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
IL275884B2
(en)
|
2018-01-26 |
2024-11-01 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
|
SG11202005235WA
(en)
|
2018-01-31 |
2020-07-29 |
Regeneron Pharma |
System and method for characterizing size and charge variant drug product impurities
|
|
TWI825066B
(zh)
|
2018-02-01 |
2023-12-11 |
美商再生元醫藥公司 |
治療性單株抗體之品質屬性的定量及模型化
|
|
JP7539834B2
(ja)
|
2018-02-01 |
2024-08-26 |
メモリアル スローン ケタリング キャンサー センター |
ガレクチン－３に対する抗体及びその使用方法
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
MA51796A
(fr)
|
2018-02-07 |
2020-12-16 |
Regeneron Pharma |
Procédés et compositions pour l'administration de protéines thérapeutiques
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
CN111771000A
(zh)
|
2018-02-28 |
2020-10-13 |
瑞泽恩制药公司 |
用于鉴定病毒污染物的系统和方法
|
|
JP7579706B2
(ja)
|
2018-03-01 |
2024-11-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
体組成を変更するための方法
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
WO2019182901A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
MX2020009989A
(es)
|
2018-03-24 |
2020-10-14 |
Regeneron Pharma |
Animales no humanos geneticamente modificados para generar anticuerpos terapeuticos contra complejos peptidos-mhc, metodos de elaboracion y usos de estos.
|
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
WO2019200022A1
(en)
|
2018-04-11 |
2019-10-17 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
IL278244B1
(en)
|
2018-04-30 |
2025-09-01 |
Regeneron Pharma |
Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof
|
|
US12338289B2
(en)
|
2018-05-03 |
2025-06-24 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
EP3790898A4
(en)
|
2018-05-10 |
2022-03-02 |
Neuracle Science Co., Ltd |
SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
|
|
US12252544B2
(en)
|
2018-05-17 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-CD63 antibodies, conjugates, and uses thereof
|
|
US20190382477A1
(en)
|
2018-06-01 |
2019-12-19 |
Compugen Ltd. |
Anti-pvrig/anti-tigit bispecific antibodies and methods of use
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
US12068729B2
(en)
|
2018-06-19 |
2024-08-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-factor XII/XIIa antibodies and uses thereof
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
MA52951A
(fr)
|
2018-06-22 |
2021-04-28 |
Genmab Holding B V |
Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
|
|
EP3810649A1
(en)
|
2018-06-22 |
2021-04-28 |
Genmab A/S |
Method for producing a controlled mixture of two or more different antibodies
|
|
JP7397445B2
(ja)
|
2018-06-26 |
2023-12-13 |
協和キリン株式会社 |
Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
|
|
AU2019295277B2
(en)
|
2018-06-26 |
2025-12-11 |
Kagoshima University |
Antibody binding to chondroitin sulfate proteoglycan-5
|
|
US11884729B2
(en)
|
2018-06-29 |
2024-01-30 |
ApitBio, Inc |
Anti-L1CAM antibodies and uses thereof
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
CA3104873A1
(en)
*
|
2018-07-10 |
2020-01-16 |
Regeneron Pharmaceuticals, Inc. |
Modifying binding molecules to minimize pre-existing interactions
|
|
US20200017600A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Variants of cd38 antibody and uses thereof
|
|
MA53123A
(fr)
|
2018-07-13 |
2021-05-19 |
Genmab As |
Thérapie à médiation par trogocytose utilisant des anticorps cd38
|
|
EA202190263A1
(ru)
|
2018-07-13 |
2021-04-21 |
Ридженерон Фармасьютикалз, Инк. |
Обнаружение и количественное определение гликозилированных пептидов
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
US12195533B2
(en)
|
2018-07-24 |
2025-01-14 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
|
|
CA3106997A1
(en)
|
2018-08-13 |
2020-02-20 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic protein selection in simulated in vivo conditions
|
|
BR112021002724A2
(pt)
|
2018-08-17 |
2021-07-20 |
Regeneron Pharmaceuticals, Inc. |
método para quantificar uma quantidade de um anticorpo heterodimérico, e, sistema de cromatografia
|
|
US11047863B2
(en)
|
2018-08-17 |
2021-06-29 |
Regeneron Pharmaceuticals, Inc. |
Methods for de novo protein sequencing
|
|
CN112888482B
(zh)
|
2018-08-23 |
2024-06-25 |
里珍纳龙药品有限公司 |
抗Fcε-R1α(FCER1A)抗体，结合FCER1A和CD3的双特异性抗原结合分子及其用途
|
|
CN112218877B
(zh)
|
2018-08-27 |
2025-07-25 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
AU2019331024A1
(en)
|
2018-08-31 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
WO2020070678A2
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
KR20210116429A
(ko)
|
2018-10-04 |
2021-09-27 |
젠맵 홀딩 비.브이. |
이중특이적 항-cd37 항체를 포함하는 제약 조성물
|
|
US20210340273A1
(en)
|
2018-10-11 |
2021-11-04 |
Inhlbrx, inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
US20230124851A1
(en)
|
2018-10-11 |
2023-04-20 |
Inhibrx, lnc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
US11208485B2
(en)
|
2018-10-11 |
2021-12-28 |
Inhibrx, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
WO2020076977A2
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
KR20210082207A
(ko)
|
2018-10-23 |
2021-07-02 |
리제너론 파아마슈티컬스, 인크. |
항-npr1 항체 및 이의 용도
|
|
JP7439077B2
(ja)
|
2018-10-25 |
2024-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ウイルスカプシドタンパク質組成の分析方法
|
|
MX2021004732A
(es)
*
|
2018-10-26 |
2021-06-04 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd38.
|
|
AU2019369421A1
(en)
|
2018-10-31 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Method and system of identifying and quantifying a protein
|
|
MA54139A
(fr)
|
2018-11-06 |
2021-09-15 |
BioNTech SE |
Formulation d'anticorps
|
|
US20220332800A1
(en)
|
2018-11-20 |
2022-10-20 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
|
WO2020106814A1
(en)
|
2018-11-21 |
2020-05-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
|
US11249089B2
(en)
|
2018-12-12 |
2022-02-15 |
Regeneron Pharmaceuticals, Inc. |
System and method of analysis of a protein using liquid chromatography-mass spectrometry
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
US11782023B2
(en)
*
|
2018-12-19 |
2023-10-10 |
Regeneron Pharmaceuticals, Inc. |
Ce-western applications for antibody development
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
LT3723858T
(lt)
|
2018-12-21 |
2022-02-10 |
Kymab Limited |
Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę
|
|
WO2020136564A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
|
CA3124762A1
(en)
|
2018-12-24 |
2020-07-02 |
Seoul National University R&Db Foundation |
Type 1 interferon neutralizing fc-fusion protein and use thereof
|
|
WO2020141452A1
(en)
|
2019-01-02 |
2020-07-09 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
EP3857236A1
(en)
|
2019-01-16 |
2021-08-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for identifying free thiols in proteins
|
|
CN113660956B
(zh)
|
2019-01-28 |
2024-10-29 |
Ab诊疗公司 |
双特异性抗体及其用途
|
|
KR20210122803A
(ko)
|
2019-01-31 |
2021-10-12 |
리제너론 파아마슈티컬스, 인크. |
항체 전하 이질성의 고유 마이크로유체 ce-ms 분석
|
|
CN113412121A
(zh)
|
2019-02-12 |
2021-09-17 |
瑞泽恩制药公司 |
使用双特异性抗体结合补体和靶抗原的组合物和方法
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
AU2020224154B2
(en)
|
2019-02-21 |
2025-05-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
CN114126714A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
MX2021010003A
(es)
|
2019-02-26 |
2021-12-10 |
Inspirna Inc |
Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
|
|
CN114173875B
(zh)
|
2019-03-01 |
2025-04-15 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
|
EP3945800A1
(en)
|
2019-04-03 |
2022-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
|
CN117178959A
(zh)
|
2019-04-04 |
2023-12-08 |
瑞泽恩制药公司 |
包括人源化凝血因子12基因座的非人动物
|
|
MX2021012335A
(es)
|
2019-04-10 |
2021-11-12 |
Regeneron Pharma |
Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
|
|
MA55881A
(fr)
|
2019-05-09 |
2022-03-16 |
Genmab Bv |
Schémas posologiques pour une combinaison d'anticorps anti-dr5 destinés à être utilisés dans le traitement du cancer
|
|
CA3140713A1
(en)
|
2019-05-21 |
2020-11-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for identifying and quantitating host cell protein
|
|
JP7610339B2
(ja)
|
2019-06-04 |
2025-01-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
|
|
MX2021014893A
(es)
|
2019-06-05 |
2022-03-11 |
Regeneron Pharma |
Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
|
|
CN113966343A
(zh)
|
2019-06-11 |
2022-01-21 |
瑞泽恩制药公司 |
结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
|
|
MA56197A
(fr)
*
|
2019-06-13 |
2022-04-20 |
Regeneron Pharma |
Procédés d'élimination de composants indésirables pendant des processus chromatographiques en plusieurs étapes
|
|
US20200399372A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
|
WO2020257604A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
|
|
WO2021007150A1
(en)
|
2019-07-08 |
2021-01-14 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
|
GB201910900D0
(en)
*
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
|
EP4010371A1
(en)
|
2019-08-08 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
MX2022001942A
(es)
|
2019-08-15 |
2022-07-27 |
Regeneron Pharma |
Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
|
|
MX2022001799A
(es)
|
2019-08-15 |
2022-03-11 |
Janssen Biotech Inc |
Materiales y metodos para fragmentos variables de cadena unica mejorados.
|
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
JP7611908B2
(ja)
|
2019-10-28 |
2025-01-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗血球凝集素抗体およびその使用方法
|
|
MX2022005330A
(es)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharma |
Moleculas de union multiespecificas con scfv en el extremo nterminal.
|
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
CN114760986A
(zh)
|
2019-11-25 |
2022-07-15 |
里珍纳龙药品有限公司 |
使用非水性乳液的持续释放调配物
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
EP4069722A1
(en)
|
2019-12-02 |
2022-10-12 |
Regeneron Pharmaceuticals, Inc. |
Peptide-mhc ii protein constructs and uses thereof
|
|
MY193353A
(en)
|
2019-12-06 |
2022-10-06 |
Regeneron Pharma |
Anti-vegf protein compositions and methods for producing the same
|
|
JP7693672B2
(ja)
|
2019-12-06 |
2025-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
|
|
JP2023506750A
(ja)
|
2019-12-11 |
2023-02-20 |
シラグ・ゲーエムベーハー・インターナショナル |
Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用
|
|
WO2021127495A1
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
IL293845A
(en)
*
|
2019-12-26 |
2022-08-01 |
Abl Bio Inc |
Method for purifying biologically active peptide by using protein a affinity chromatography
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
CN115280151A
(zh)
|
2020-01-08 |
2022-11-01 |
瑞泽恩制药公司 |
使用氨基酸增强质谱分析中的信号
|
|
WO2021144457A1
(en)
|
2020-01-16 |
2021-07-22 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
|
MX2022008973A
(es)
|
2020-01-21 |
2022-08-11 |
Regeneron Pharma |
Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
|
|
AU2021213720A1
(en)
|
2020-01-27 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Tandem Mass Tag multiplexed quantitation of post-translational modifications of proteins
|
|
KR20220133248A
(ko)
|
2020-01-28 |
2022-10-04 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법
|
|
IL294879A
(en)
|
2020-01-29 |
2022-09-01 |
Inhibrx Inc |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
WO2021155215A1
(en)
|
2020-01-30 |
2021-08-05 |
Regeneron Pharmaceuticals, Inc. |
Platform for native liquid chromatography-mass spectrometry
|
|
IL294907A
(en)
|
2020-01-31 |
2022-09-01 |
Regeneron Pharma |
High confidence compound identification by liquid chromatography-mass spectrometry
|
|
US20230081547A1
(en)
|
2020-02-07 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
|
WO2021163170A1
(en)
|
2020-02-11 |
2021-08-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and uses thereof
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
WO2021194839A1
(en)
|
2020-03-25 |
2021-09-30 |
Eli Lilly And Company |
Multispecific binding proteins and methods of developing the same
|
|
IL296514A
(en)
|
2020-03-30 |
2022-11-01 |
Univ Mie |
Bispecific antibody
|
|
EP4136442A1
(en)
|
2020-04-14 |
2023-02-22 |
Regeneron Pharmaceuticals, Inc. |
Ultraviolet monitoring of chromatography performance by orthogonal partial least squares
|
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
CN115803009A
(zh)
|
2020-05-08 |
2023-03-14 |
瑞泽恩制药公司 |
用于治疗眼病和癌症的vegf阱和微阱及方法
|
|
WO2021228904A1
(en)
|
2020-05-11 |
2021-11-18 |
Academisch Medisch Centrum |
Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof
|
|
KR20230009430A
(ko)
|
2020-05-12 |
2023-01-17 |
리제너론 파아마슈티컬스, 인크. |
신규 il10 효능제 및 그의 사용 방법
|
|
WO2021231366A1
(en)
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-glp1r antagonist antibodies and methods of use thereof
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
WO2021263146A2
(en)
|
2020-06-26 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ace2 locus
|
|
JP2023534726A
(ja)
|
2020-07-23 |
2023-08-10 |
ジェンマブ ビー．ブイ． |
多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
|
|
US11725052B2
(en)
|
2020-08-18 |
2023-08-15 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
AU2021327238A1
(en)
|
2020-08-20 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists
|
|
EP4204450A4
(en)
|
2020-08-26 |
2024-11-13 |
Marengo Therapeutics, Inc. |
MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES
|
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
|
|
EP4204096A4
(en)
|
2020-08-26 |
2024-10-02 |
Marengo Therapeutics, Inc. |
ANTIBODY MOLECULES BINDING TO NKP30 AND USES THEREOF
|
|
WO2022047108A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
US20220090060A1
(en)
|
2020-09-11 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
|
JP2023543152A
(ja)
|
2020-09-18 |
2023-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
|
|
WO2022069724A1
(en)
|
2020-10-02 |
2022-04-07 |
Genmab A/S |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
|
US20230374148A1
(en)
|
2020-10-15 |
2023-11-23 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
|
WO2022100613A1
(zh)
|
2020-11-10 |
2022-05-19 |
上海齐鲁制药研究中心有限公司 |
针对密蛋白18a2和cd3的双特异性抗体及其应用
|
|
US12239687B2
(en)
|
2020-11-25 |
2025-03-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
CN114539416B
(zh)
*
|
2020-11-26 |
2024-11-08 |
盛禾(中国)生物制药有限公司 |
一种双特异性抗体的层析纯化工艺
|
|
KR20230121854A
(ko)
|
2020-12-17 |
2023-08-21 |
리제너론 파아마슈티컬스, 인크. |
단백질-캡슐화 마이크로겔의 제작
|
|
IL303542A
(en)
|
2020-12-18 |
2023-08-01 |
Regeneron Pharma |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
AU2021400324A1
(en)
|
2020-12-20 |
2023-07-13 |
Regeneron Pharmaceuticals, Inc. |
Methods for identification of scrambled disulfides in biomolecules
|
|
KR20230162775A
(ko)
*
|
2021-01-11 |
2023-11-28 |
아디맵 엘엘씨 |
우선적인 ch3 이량체화를 위해 조작된 변이체 ch3 도메인,이를 포함하는 다중-특이적 항체, 및 이의 제조 방법
|
|
CA3202197A1
(en)
|
2021-01-20 |
2022-07-28 |
Reginald Smith |
Methods of improving protein titer in cell culture
|
|
EP4284828A1
(en)
|
2021-01-28 |
2023-12-06 |
Talem Therapeutics LLC |
Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
|
|
HUE071594T2
(hu)
|
2021-01-28 |
2025-09-28 |
Regeneron Pharma |
Készítmények és módszerek a citokinfelszabadulási szindróma kezelésére
|
|
MX2023009112A
(es)
|
2021-02-04 |
2023-10-17 |
Genuv Inc |
Anticuerpo anti-pd-1 y uso del mismo.
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
EP4302098A1
(en)
|
2021-03-03 |
2024-01-10 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
WO2022200525A1
(en)
|
2021-03-26 |
2022-09-29 |
Innate Pharma |
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
|
|
EP4317435A1
(en)
|
2021-03-29 |
2024-02-07 |
Daiichi Sankyo Company, Limited |
Stable multispecific molecule and use thereof
|
|
AR125255A1
(es)
|
2021-04-02 |
2023-06-28 |
Regeneron Pharma |
Métodos de predicción y modulación de la glicación de una proteína
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
CN117597359A
(zh)
|
2021-04-08 |
2024-02-23 |
马伦戈治疗公司 |
与tcr结合的多功能分子及其用途
|
|
MX2023012724A
(es)
|
2021-04-27 |
2024-02-08 |
Amgen Inc |
Modulación de la calidad de producto de anticuerpos multiespecíficos asimétricos a través del uso de la temperatura.
|
|
JP2024517844A
(ja)
|
2021-05-04 |
2024-04-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性ｆｇｆ２１受容体アゴニスト及びそれらの使用
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
WO2022241235A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
US20240239907A1
(en)
|
2021-05-25 |
2024-07-18 |
Edelweiss Immune Inc |
C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
|
|
CA3220848A1
(en)
|
2021-06-01 |
2022-12-08 |
Timothy Riehlman |
Microchip capillary electrophoresis assays and reagents
|
|
MX2023014647A
(es)
|
2021-06-09 |
2024-01-31 |
Innate Pharma |
Proteinas de union a nkp46 multiespecificas.
|
|
CN117529504A
(zh)
|
2021-06-09 |
2024-02-06 |
先天制药公司 |
结合至cd20、nkp46、cd16并缀合至il-2的多特异性抗体
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
AU2022293999A1
(en)
|
2021-06-14 |
2023-11-30 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
IL310221A
(en)
|
2021-07-19 |
2024-03-01 |
Regeneron Pharma |
IL12 receptor agonists and methods of using them
|
|
TW202322850A
(zh)
*
|
2021-08-05 |
2023-06-16 |
美商美國禮來大藥廠 |
抗體最佳化
|
|
TW202322846A
(zh)
|
2021-08-16 |
2023-06-16 |
美商再生元醫藥公司 |
新穎的il27受體促效劑及其使用方法
|
|
US20240360233A1
(en)
|
2021-08-27 |
2024-10-31 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
|
KR20240051280A
(ko)
|
2021-09-06 |
2024-04-19 |
젠맵 에이/에스 |
Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
|
|
AR127006A1
(es)
|
2021-09-08 |
2023-12-06 |
Regeneron Pharma |
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
|
|
JP2024539928A
(ja)
|
2021-11-04 |
2024-10-31 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
改変ｃａｃｎｇ１遺伝子座を含む非ヒト動物
|
|
JP2024544534A
(ja)
|
2021-11-11 |
2024-12-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ２０－ｐｄ１結合分子及びその使用方法
|
|
IL312813A
(en)
|
2021-11-24 |
2024-07-01 |
Regeneron Pharma |
Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
|
|
WO2023100829A1
(ja)
|
2021-11-30 |
2023-06-08 |
第一三共株式会社 |
プロテアーゼ分解性マスク抗体
|
|
US20230250170A1
(en)
|
2021-12-06 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
|
EP4444089A1
(en)
|
2021-12-08 |
2024-10-16 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
|
JP2025502061A
(ja)
|
2022-01-07 |
2025-01-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
再発性卵巣癌を、二重特異性抗ｍｕｃ１６×抗ｃｄ３抗体単独で、または抗ｐｄ－１抗体と組み合わせて治療する方法
|
|
TW202337900A
(zh)
|
2022-01-12 |
2023-10-01 |
美商再生元醫藥公司 |
改良使用親和層析的異二聚蛋白質自雜質之解析的方法
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
US20250170255A1
(en)
|
2022-02-09 |
2025-05-29 |
Daiichi Sankyo Company, Limited |
Environmentally-responsive masked antibody and use thereof
|
|
CN118613498A
(zh)
|
2022-02-11 |
2024-09-06 |
瑞泽恩制药公司 |
用于筛选4R Tau靶向剂的组合物和方法
|
|
EP4482585A1
(en)
|
2022-02-23 |
2025-01-01 |
Xencor, Inc. |
Anti-cd28 x anti-psma antibodies
|
|
EP4482531A1
(en)
|
2022-02-23 |
2025-01-01 |
Bright Peak Therapeutics AG |
Immune antigen specific il-18 immunocytokines and uses thereof
|
|
WO2023164640A1
(en)
|
2022-02-24 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
|
US20230340128A1
(en)
|
2022-02-24 |
2023-10-26 |
Xencor, Inc. |
Anti-cd28 x anti-msln antibodies
|
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
|
TW202400232A
(zh)
|
2022-03-16 |
2024-01-01 |
日商第一三共股份有限公司 |
多特異性分子與免疫檢查點抑制劑之組合
|
|
CN119677534A
(zh)
|
2022-03-17 |
2025-03-21 |
瑞泽恩制药公司 |
使用双特异性抗muc16×抗cd3抗体单独或与抗pd-1抗体组合来治疗复发性上皮样肉瘤的方法
|
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
|
AU2023254191A1
(en)
|
2022-04-11 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
US20250332287A1
(en)
|
2022-04-29 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
KR20250024872A
(ko)
|
2022-05-11 |
2025-02-19 |
리제너론 파마슈티칼스 인코포레이티드 |
다중특이적 결합 분자 전구단백질 및 이의 용도
|
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
JP2025516633A
(ja)
|
2022-05-12 |
2025-05-30 |
ジェンマブ エー／エス |
併用療法においてｃｄ２７に結合する能力を有する結合剤
|
|
IL316751A
(en)
|
2022-05-16 |
2025-01-01 |
Regeneron Pharma |
Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies
|
|
KR20250011926A
(ko)
|
2022-05-18 |
2025-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
Cd38 및 4-1bb에 결합하는 다중특이적 항원 결합 분자, 및 이의 용도
|
|
CA3257348A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharma |
INTERLEUKIN-2 PROPROTEINS AND THEIR USES
|
|
EP4536690A1
(en)
|
2022-06-04 |
2025-04-16 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
CN119584978A
(zh)
|
2022-06-07 |
2025-03-07 |
再生元制药公司 |
用于调节t细胞活性的多特异性分子及其用途
|
|
WO2024020199A1
(en)
|
2022-07-21 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Native microfluidic ce-ms analysis of antibody charge heterogeneity
|
|
KR20250048010A
(ko)
|
2022-07-29 |
2025-04-07 |
리제너론 파마슈티칼스 인코포레이티드 |
변형된 트랜스페린 수용체 좌위를 포함하는 비-인간 동물
|
|
CA3263494A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharma |
ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE
|
|
CA3261203A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharma |
COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE
|
|
US20240043560A1
(en)
|
2022-08-02 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies
|
|
JP2025529805A
(ja)
|
2022-08-18 |
2025-09-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
インターフェロンプロタンパク質及びその使用
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
JP2025534206A
(ja)
|
2022-09-15 |
2025-10-15 |
アビディキュア アイピー ビー．ブイ． |
Ｎｋ細胞を刺激するための多重特異性抗原結合タンパク質及びその使用
|
|
US20240224964A9
(en)
|
2022-09-29 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
CN120282798A
(zh)
|
2022-10-10 |
2025-07-08 |
瑞泽恩制药公司 |
用于降低需要实体器官移植的受试者中的同种抗体水平的方法
|
|
CN120076823A
(zh)
|
2022-10-21 |
2025-05-30 |
达科纳治疗有限公司 |
针对il-18受体的异聚体激动性抗体
|
|
WO2024092031A1
(en)
|
2022-10-25 |
2024-05-02 |
Seismic Therapeutic, Inc. |
VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
|
|
US20240150474A1
(en)
|
2022-10-27 |
2024-05-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
CN120500498A
(zh)
|
2022-11-14 |
2025-08-15 |
瑞泽恩制药公司 |
用于成纤维细胞生长因子受体3介导的至星形胶质细胞的递送的组合物及方法
|
|
CN120456916A
(zh)
|
2022-11-14 |
2025-08-08 |
瑞泽恩制药公司 |
抗fgfr3抗体和抗原结合片段及其使用方法
|
|
WO2024123698A1
(en)
|
2022-12-08 |
2024-06-13 |
Regeneron Pharmaceuticals, Inc. |
Methods to characterizing a fragment crystallizable domain of a bispecific antibody
|
|
CN120712281A
(zh)
|
2022-12-16 |
2025-09-26 |
瑞泽恩制药公司 |
结合到aav颗粒的抗原结合分子和用途
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
EP4638729A1
(en)
|
2022-12-23 |
2025-10-29 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
AU2024207469A1
(en)
|
2023-01-13 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2024151978A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
KR20250151402A
(ko)
|
2023-01-20 |
2025-10-21 |
인베티엑스 인코포레이티드 |
반려 동물에서 사용하기 위한 이중특이적 결합제
|
|
CN120677178A
(zh)
|
2023-02-13 |
2025-09-19 |
瑞泽恩制药公司 |
用抗人cacng1抗体治疗肌肉相关病症
|
|
AU2024223918A1
(en)
|
2023-02-17 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
CN121057744A
(zh)
|
2023-02-28 |
2025-12-02 |
再生元制药公司 |
多价抗刺突蛋白结合分子及其用途
|
|
US20240287186A1
(en)
|
2023-02-28 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
T cell activators and methods of use thereof
|
|
AU2024237581A1
(en)
|
2023-03-14 |
2025-10-02 |
Xencor, Inc. |
Anti-cd28 compositions
|
|
AU2024240129A1
(en)
|
2023-03-17 |
2025-10-09 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
TW202500193A
(zh)
|
2023-03-22 |
2025-01-01 |
美商信立泰生物醫藥公司 |
抗５ｔ４抗原結合結構域、抗體－藥物共軛體及彼等之使用方法
|
|
WO2024211796A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
CN121057752A
(zh)
|
2023-04-07 |
2025-12-02 |
达科纳治疗有限公司 |
铰链经修饰的双特异性抗体
|
|
WO2024216221A1
(en)
|
2023-04-14 |
2024-10-17 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
|
WO2024216226A1
(en)
|
2023-04-14 |
2024-10-17 |
Xencor, Inc. |
Anti-cd28 x anti-enpp3 antibodies
|
|
AU2024265540A1
(en)
|
2023-05-01 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
AU2024265507A1
(en)
|
2023-05-02 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
WO2024233926A1
(en)
|
2023-05-10 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
US20240376229A1
(en)
|
2023-05-12 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
US20240400703A1
(en)
|
2023-05-12 |
2024-12-05 |
Genmab A/S |
Antibodies capable of binding to ox40, variants thereof and uses thereof
|
|
US20250019450A1
(en)
|
2023-05-19 |
2025-01-16 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to il12 receptor
|
|
US20240408246A1
(en)
|
2023-06-08 |
2024-12-12 |
Regeneron Pharmaceuticals, Inc. |
Animal Model With Rapid Onset Of Alzheimer's Amyloid Beta Plaque Pathology
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
|
WO2024258785A1
(en)
|
2023-06-11 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
WO2024258870A2
(en)
|
2023-06-12 |
2024-12-19 |
Amgen Inc. |
Lymphotoxin beta receptor agonist binding proteins
|
|
WO2024259206A1
(en)
|
2023-06-16 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
|
|
TW202519547A
(zh)
|
2023-07-10 |
2025-05-16 |
美商再生元醫藥公司 |
雙特異性PD-L1x4-1BB抗體及其使用方法
|
|
TW202519559A
(zh)
|
2023-07-10 |
2025-05-16 |
美商再生元醫藥公司 |
雙特異性PD-L1xCD28抗體及其使用方法
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
WO2025019789A1
(en)
|
2023-07-19 |
2025-01-23 |
Regeneron Pharmaceuticals, Inc. |
ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
|
|
TW202513801A
(zh)
|
2023-07-28 |
2025-04-01 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
|
|
WO2025029662A1
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr: acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025030044A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025030041A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
|
|
US20250188166A1
(en)
|
2023-08-23 |
2025-06-12 |
Bright Peak Therapeutics Ag |
Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
|
|
US20250122299A1
(en)
|
2023-08-28 |
2025-04-17 |
Xencor, Inc. |
ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
|
|
WO2025049591A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-cxcr4 antibodies and uses thereof
|
|
US20250179197A1
(en)
|
2023-10-23 |
2025-06-05 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
WO2025090973A2
(en)
|
2023-10-27 |
2025-05-01 |
Xencor, Inc. |
Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
US20250163468A1
(en)
|
2023-11-21 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
|
|
WO2025117869A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent ovarian cancer and endometrial cancer with bispecific anti-muc16 x anti-cd28 antibodies in combination with anti-pd-1 antibodies or bispecific anti-muc16 x anti-cd3 antibodies
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
WO2025128652A1
(en)
|
2023-12-12 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025151806A1
(en)
|
2024-01-11 |
2025-07-17 |
Regeneron Pharmaceuticals, Inc. |
P75 neurotrophin receptor (p75ntr)-binding proteins and p75ntr-mediated delivery to the nervous system
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025171124A1
(en)
|
2024-02-07 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025184603A2
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025191137A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of trop2-specific antigen binding proteins and cytokines
|
|
US20250297006A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025213061A2
(en)
|
2024-04-04 |
2025-10-09 |
Ethyreal Bio, Inc. |
Anti-tshr antibodies and uses thereof
|
|
WO2025221728A2
(en)
|
2024-04-15 |
2025-10-23 |
Janssen Biotech, Inc. |
Ltbr binding molecules and uses thereof
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025240287A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
|
|
WO2025244973A1
(en)
|
2024-05-20 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|